Loading
companiesCompany
Blueprint Medicines
Blueprint Medicines invented Ayvakit, a pill approved for systemic mastocytosis and for a rare gut tumour called GIST that carries a specific mutation. The French drug maker Sanofi bought the company in 2025.
Overview
Blueprint Medicines is a Cambridge, Massachusetts kinase medicine company, now a Sanofi company. Its approved product, Ayvakit/Ayvakyt (avapritinib), is a KIT and PDGFRA inhibitor approved for advanced and indolent systemic mastocytosis and, per the company's site, for certain gastrointestinal stromal tumours (GIST). The pipeline includes elenestinib, a next-generation KIT inhibitor for systemic mastocytosis, and BLU-808, an oral wild-type KIT inhibitor for mast cell-driven allergic and inflammatory disease. Sanofi and Blueprint announced a definitive agreement on 2 June 2025 at 129 US dollars per share in cash (about 9.1 billion US dollars equity value) plus a contingent value right of up to 6 US dollars per share; the tender offer expired on 17 July 2025 with about 70.9 percent of shares tendered and the merger closed shortly after. Blueprint's former Nasdaq ticker was BPMC.
Headquarters
Cambridge, MA, US
Scorecard
All companies#240of 1244 companies, score 21
- approved products +6
- targets +2
- modalities +2
- regions +5
- registry trials +6
1 approved, 0 in phase 3, 0 earlier, 1 targets, 10 registry studies. Formula on the scorecards page.
Funding
All startupsAcquiredAcquired by Sanofi
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · 129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer completed July 2025 | 2025 | $9.1B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
ApprovedSmall-molecule kinase inhibitor (RET)
Pralsetinib · Gavreto
Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.
Notes
top- Founding year and IPO (2015) not sourced. The company website blocked curl (Cloudflare) but was fetched successfully with WebFetch. The GIST indication statement rests on the website summary; the Sanofi release frames the deal around systemic mastocytosis and immunology.
Similar pages
- TreatmentAvapritinib
- Key paperARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
- CancerPDGFRA D842V-mutant GIST
- TrialLIBRETTO-431
Shares ARROW (thyroid cohorts), RET fusion-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
- CompanyRelay Therapeutics
- TrialA Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
Shares ARROW (thyroid cohorts), RET fusion-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
- PersonGeorge D. Demetri
Shares KIT, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule kinase inhibitor (RET)
Pralsetinib · Gavreto